OCUL
NASDAQOcular Therapeutix Inc.
Price$10.11-0.31 (-2.98%)
01:30 PM07:45 PM
News · 26 weeks71+88%
2025-12-282026-06-21
Mix3490d
- Insider14(41%)
- Other13(38%)
- SEC Filings5(15%)
- Earnings2(6%)
Latest news
25 items- PROcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company’s new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards granted to Ms. Allison were effective as of June 15, 2026 and consist of a non-statutory stock option award to purchase up t
- INSIDEROfficer Dugel Pravin gifted 50,092 shares and received a gift of 50,092 shares, decreasing direct ownership by 2% to 2,547,078 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- PROcular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements Complete AXPAXLI NDA package in wet AMD planned to be submitted in 4Q 2026 SOL-R efficacy data no longer part of the AXPAXLI NDA submission plan Ocular will evaluate superiority of AXPAXLI vs aflibercept (8mg) Q6M at Week 96 as a key secondary endpoint of the SOL-R trial SOL-R to remain masked through Week 96, with topline results now expected in 1Q 2028 New secondary endpoint addition to SOL-R has
- INSIDERDirector Warden Charles M was granted 14,000 shares, increasing direct ownership by 16% to 100,464 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERDirector Graves Adrienne L was granted 14,000 shares, increasing direct ownership by 28% to 64,000 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERChief Financial Officer Robins Jason Shand was granted 15,441 shares, increasing direct ownership by 29% to 68,097 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERDirector Hong Seung Suh was granted 14,000 shares, increasing direct ownership by 30% to 60,933 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERDirector Lindstrom Richard L Md was granted 14,000 shares, increasing direct ownership by 6% to 260,933 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERDirector Raines Merilee was granted 14,000 shares, increasing direct ownership by 30% to 60,933 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERDirector Williams Leslie J. was granted 14,000 shares, increasing direct ownership by 27% to 65,433 units (SEC Form 4)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- SECOcular Therapeutix Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
- INSIDERChief Medical Officer Waheed Nadia sold $122,628 worth of shares (14,828 units at $8.27), decreasing direct ownership by 5% to 300,079 units (SEC Form 4) (tax liability)4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- PROcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to seven newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of June 1, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 51,775 shares of Ocular's comm
- PROcular Therapeutix™ to Participate in Clinical Trials at the Summit 2026BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada. Clinical Trials at the Summit (CTS) 2026 Presentation Details: Fireside Chat with Wiley Chambers, MDFireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PTModerators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer Presentation Title: OTX-TKI: Overview of ScienceSession: Clinical Trials Addressing nAMD, DME, and DRPresentation D
- PROcular Therapeutix™ to Host Investor Day on June 17, 2026In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD Company to highlight AXPAXLI™ wet AMD NDA submission plan, updates on SOL-R, SOL-X, and registrational diabetic retinopathy program, and an overview of the planned commercialization approach for AXPAXLI, if approved The live event will take place in New York City on June 17, 2026, starting at 2:00 PM ET BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, will host
- INSIDEROfficer Dugel Pravin received a gift of 394,696 shares, sold $173,479 worth of shares (21,156 units at $8.20) and gifted 394,696 shares, decreasing direct ownership by 0.81% to 2,597,170 units (SEC Form 4) to cover taxes4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERChief Development Officer Kaiser Peter sold $24,329 worth of shares (2,967 units at $8.20), decreasing direct ownership by 1% to 266,141 units (SEC Form 4) to satisfy withholding obligation4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERChief Scientific Officer Heier Jeffrey S. sold $24,748 worth of shares (3,018 units at $8.20), decreasing direct ownership by 0.93% to 320,350 units (SEC Form 4) to cover withholding tax4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- INSIDERChief Strategy Officer Nayak Sanjay sold $15,236 worth of shares (1,858 units at $8.20), decreasing direct ownership by 0.56% to 328,795 units (SEC Form 4) to satisfy withholding obligation4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
- PROcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to twelve newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of May 4, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 127,650 shares of Ocular's comm
- SECSEC Form 10-Q filed by Ocular Therapeutix Inc.10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
- SECOcular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
- PROcular Therapeutix™ Reports First Quarter 2026 Financial Results and Business HighlightsEnrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI's unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline read
- SECSEC Form DEFA14A filed by Ocular Therapeutix Inc.DEFA14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
- SECSEC Form DEF 14A filed by Ocular Therapeutix Inc.DEF 14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
OCUL FAQ
7 questionsWhat does Ocular Therapeutix Inc. do?
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the...Where does OCUL stock trade?
Ocular Therapeutix Inc. (OCUL) is listed on NASDAQ.What sector and industry is OCUL in?
Ocular Therapeutix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ocular Therapeutix Inc. go public?
Ocular Therapeutix Inc. (OCUL) completed its IPO in 2014.What are analysts saying about OCUL?
Ocular Therapeutix Inc. has had 8 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Buy with a $2100.00 price target on 2025-09-15. Recent price targets range from $1100.00 to $2100.00.What companies are similar to OCUL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare OCUL side-by-side with any of them on Quantisnow.How can I track OCUL on Quantisnow?
Quantisnow aggregates Ocular Therapeutix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OCUL to receive live email and push alerts on every new disclosure.